United Kingdom orders 90 million vaccine doses from Pfizer, Valneva

United Kingdom orders 90 million vaccine doses from Pfizer, Valneva

Doses of the vaccine were given to 1,077 healthy adults aged between 18 and 55 in five United Kingdom hospitals in April and May as part of the phase one clinical trial and results, published in the Lancet' medical journal.

Oxford University have made a promising development on their vaccine.

In a trial on 543 people, the vaccine was able to generate immune responses in healthy volunteers, results published Monday showed. The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial program to confirm this.

Last week, blood samples of volunteers taken by researchers at Oxford showed both antibodies and T cells, which are a component of the immune system.

The government has already said it would purchase 100 million doses of a vaccine now being trialed by Oxford University in partnership with AstraZeneca. The vaccine was administered to three healthy persons in the age group of 30-40 years who volunteered for the objective.

The vaccine - called ChAdOx1 nCoV-19 - uses a weakened version of a common cold virus (adenovirus) which causes infections in chimpanzees.

France's Valneva is in talks with the European Union about supplying the bloc with its possible COVID-19 vaccine, Chief Executive Thomas Lingelbach said on Monday after striking a deal with Britain.

At least eight large scale coronavirus vaccine trials are expected to take place in the UK.

The study follows positive news from the U.S. last week, when biotech company Moderna said it would start the final stage of trials on its vaccine this month after initial tests on a small group of volunteers were successful.

That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.

Amidst this race, the World Health Organization (WHO) believes that one or two vaccines may be available by the end of this year.

He said the phase 3 trials are the most important event as they will determine whether the immunological responses triggered by multiple vaccine candidates actually confer immunity. Earlier, the government had already bought 10 million doses of the vaccine of Oxford.

The UK government has also launched a new website, the NHS COVID-19 vaccine research registry, to allow members of the public to register interest and be contacted to participate in clinical studies.

Those who received the experimental COVID-19 vaccine developed T-cells and antibodies that can fight the SARS-CoV-2 virus or the novel coronavirus as more people know it, giving a hugely promising result.

Related Articles